Intercell AG

EANS-News: Swiss authorities grant product approval for IXIARO®

Intercell's vaccine to help prevent Japanese Encephalitis now available in Switzerland

@@start.t1@@--------------------------------------------------------------------------------   Corporate news transmitted by euro adhoc. The issuer/originator is solely   responsible for the content of this announcement. --------------------------------------------------------------------------------@@end@@

Company Information

Subtitle: Intercell's vaccine to help prevent Japanese Encephalitis now available in Switzerland

Vienna (Austria), July 13, 2010 (euro adhoc) - Intercell AG (VSE: ICLL) announces that Swissmedic has approved IXIARO®, its vaccine against Japanese Encephalitis. IXIARO®, which is distributed and marketed by Novartis, is now available in Switzerland.

The decision by the Swiss authorities represents another important milestone for the licensure process initiated for selected attractive market segments. Intercell's vaccine, which helps to prevent Japanese Encephalitis, has already been approved and launched in the USA, Europe, Canada and Australia.

"The Swissmedic approval is great news and another important step in the product's global reach", states Thomas Lingelbach, Chief Operating Officer of Intercell.

IXIARO® is a modern purified, inactivated vaccine for active immunization of adults against infections caused by the Japanese Encephalitis Virus. IXIARO® is manufactured at Intercell's proprietary manufacturing facility in Scotland using tissue culture rather than live organisms.

@@start.t2@@end of announcement                                                 euro adhoc

ots Originaltext: Intercell AG
Im Internet recherchierbar:

Further inquiry note:
Intercell AG
Lucia Malfent
Vice President, Global Head Corporate Communications
Tel. +43 1 20620-1303

Branche: Biotechnology
ISIN:      AT0000612601
WKN:        A0D8HW
Index:    ATX Prime, ATX
Börsen:  Wien / official market

Weitere Meldungen: Intercell AG

Das könnte Sie auch interessieren: